Financial Data and Key Metrics Changes - In 2025, total revenues reached nearly $1.5 billion, with a year-over-year growth of 9% driven primarily by proprietary products generating approximately $1.2 billion in net sales [9][10] - GAAP net income for the year was $241.7 million, with adjusted EBITDA of $394 million [11][18] - The company ended the year with $1.3 billion in cash and total investments [12] Business Line Data and Key Metrics Changes - VIVITROL net sales were $467.9 million, reflecting a 2% growth year-over-year [24] - ARISTADA net sales reached $370 million, showing a 7% growth year-over-year [26] - LYBALVI net sales grew 24% year-over-year to $346.7 million [27] - LUMRYZ generated approximately $279 million in net sales in 2025, with around 3,500 patients on therapy by year-end [30] Market Data and Key Metrics Changes - The company expects total revenues for 2026 to be in the range of $1.73 billion to $1.84 billion, driven primarily by proprietary products [13][14] - Manufacturing and royalty revenues for 2026 are anticipated to be between $210 million and $240 million [15] - The estimated market for oxybate-eligible patients with narcolepsy is around 50,000, indicating significant growth potential for LUMRYZ [32] Company Strategy and Development Direction - The acquisition of Avadel is seen as a strategic milestone, enhancing the company's entry into the commercial sleep medicine market and providing a platform for launching alixorexton [6][12] - The company plans to initiate the phase III Brilliance program for alixorexton in narcolepsy, with expectations of significant advancements in treatment [34] - The focus remains on operational discipline, efficient capital allocation, and investing in high-potential growth drivers, particularly in the orexin portfolio [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong financial position and the potential for growth in 2026, emphasizing the importance of the Avadel acquisition [12][23] - The company is committed to delivering shareholder growth and maintaining a strong cash flow positive profile despite expected GAAP net losses due to accounting for the acquisition [18] - Management highlighted the importance of ongoing clinical trials and the potential for alixorexton to transform narcolepsy management [40] Other Important Information - The company plans to initiate a multi-dose phase Ib study for ALKS 7290 in ADHD and a phase IIa study for ALKS 4510 in fatigue associated with neurodegenerative disorders [38][39] - The transition of CEO leadership from Richard Pops to Blair Jackson is set to occur in the summer, with Pops continuing as chairman [40] Q&A Session Summary Question: Phase III trial design and AE profile - Management indicated that the orexin 2 receptor agonists are generally well tolerated, and the split dosing is designed to maximize efficacy while minimizing side effects [44][46] Question: Potential synergies from Avadel acquisition - The integration of the Avadel commercial team is progressing well, with expectations of future synergies as the company prepares to launch alixorexton [48][49] Question: Evidence needed for payer reimbursement for both oxybates and orexin agonists - Management believes that both treatments will be important for certain patients, and they plan to generate data to support reimbursement for this cohort [51][52] Question: Internal bar for ESS in LUMRYZ phase III - Management expects the data from the IH study to mirror previous successful programs, with key secondaries being important for prescriber confidence [56][60] Question: Current understanding of NT1 versus NT2 and IH dynamics - Management noted that the narcolepsy market represents a significant opportunity, with ongoing efforts to understand the IH market better [66]